The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early development of progressive arthropathy, alongside higher treatment-related costs.
| INTRODUC TI ON
Haemophilia A and B are rare bleeding disorders caused by a deficiency or lack of clotting factor VIII (FVIII) or factor IX (FIX), respectively. For patients with severe haemophilia (clotting factor <0.01 IU/mL; <1% of normal), standard therapy should be prophylactic treatment with replacement factor FVIII/FIX. 1 The development of neutralising antibodies (inhibitors) against FVIII or FIX is the most serious complication of haemophilia treatment, 2,3 occurring in 20%-30% of patients with severe haemophilia A, 5%-10% of patients with mild-to-moderate haemophilia A, and fewer than 5% of patients with severe haemophilia B.
1 These antibodies render replacement therapy ineffective, with a consequent increase in the risk of serious bleeding and an earlier onset of progressive arthropathy, 3, 4 and also higher treatment-related costs. 5 While inhibitors usually develop within the first 20 exposure days and thus are an issue in young patients who receive prophylaxis, 6 inhibitors are also a concern for older patients.
7
Patients with haemophilia and inhibitors and/or their caregiver(s)
report reduced health-related quality of life (QoL) compared with those unaffected by inhibitors, 8, 9 and this is particularly apparent as patients grow older. 10 Factors leading to an impaired QoL in patients with inhibitors include frequent bleeds, pain, higher incidences of mobility-related problems, hospitalisations, school and work absenteeism, difficulty maintaining a job 8 and intensive treatment regimens that often require significant time commitments and which can be financially and emotionally demanding for both patients and caregivers. 5, 8 High-intensity treatment regimens requiring rigorous adherence can also be challenging and non-adherence can reduce therapy success rates, 8 which further impacts a patient's psychosocial wellbeing. For the caregivers of children with inhibitors, disappointment, isolation and general strain were significant among the reported burdens.
9
While the recently approved non-factor therapy, emicizumab (Hemlibra ® , Roche, Basel, Switzerland) provides new treatment options for patients with haemophilia A and inhibitors against FVIII, the authors do not recommend emicizumab as first-line therapy in these patients (this is discussed in more detail in Section 3.1). The preferred management strategy for patients with haemophilia A who develop high-titre inhibitors is antibody eradication via immune tolerance induction (ITI). 2, 3 Bleeding episodes can be treated with bypassing agents 3, 11 and potentially with novel haemostatic agents currently in development. 12 The majority of patients with haemophilia A and inhibitors will become "immune tolerant" to FVIII following ITI, with international registries reporting success rates of 51%-79%. [13] [14] [15] [16] However, some patients will be difficult to tolerise and/or are unresponsive to first-line ITI, and these patients are the most complicated to treat. 3, 17 ITI may also be attempted in patients with haemophilia B and high-titre FIX inhibitors, but it is utilised less frequently than in those with haemophilia A due to a general lack of experience of its use in haemophilia B and lower overall success rates, as well as concern about anaphylactic reactions and development of nephrotic syndrome. 2, 3, 13 The lack of data for ITI in patients with haemophilia B and inhibitors means that the optimal approach for achieving successful outcomes in these patients has not been clarified. 2, 13 This review summarises currently available treatment options for patients with inhibitors, starting with the treatment of bleeds and prophylaxis but focussing largely on ITI regimens, including those ITI strategies that can be used in difficult-to-treat patients. We also propose several non-ITI treatment alternatives that may be helpful in managing patients with haemophilia and inhibitors. 25 Emicizumab has a mechanism of action that is not based on replacement or bypass therapy; it is a bispecific monoclonal antibody to activated FIX and factor X, which mimics the cofactor function of FVIII and can be administered subcutaneously. 26, 27 Phase III trial data showed that, in patients with haemophilia A and inhibitors, emicizumab prophylaxis was associated with a significant reduction in the annualised bleeding rate compared with no prophylaxis (P < 0.001). 26 A good safety profile was reported for emicizumab administered alone or in conjunction with rFVIIa alone. However, in this study, thrombotic microangiopathy and thrombosis (in two participants each) developed following administration of multiple infusions of pd-aPCC for breakthrough bleeds while receiving emicizumab prophylaxis; this resolved after pd-aPCC treatment was stopped. 26 Another trial participant receiving emicizumab developed thrombotic microangiopathy following treatment with pd-aPCC for rectal haemorrhage; however, the rectal bleeding was recurrent and eventually fatal. 25 In addition to the above fatality, a further four deaths have subsequently been reported in adults treated with emicizumab, one of whom was being treated in the US expanded access programme and three under compassionate use requests. 29 As with the death during the phase III trial, in all four of these instances, the treating physician considered that the cause was unrelated to emicizumab.
| MANAG ING B LEEDS IN PATIENTS WITH INHIB ITOR S
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While emicizumab prophylaxis provides an alternative treatment option for patients with haemophilia A and inhibitors, in general, the authors do not recommend that emicizumab be con- 
| Bypassing agents
Prophylaxis with bypassing agents has been shown to reduce bleeding events, prevent or delay the development of target joints and arthropathy, as well as to delay the progression of existing joint disease in certain patients, despite lower efficacy compared with FVIII prophylaxis in patients without inhibitors. 30, 31 The potential benefits of prophylaxis in preventing arthropathy are particularly relevant for children with unaffected joints undergoing ITI.
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Few guidelines on prophylactic use of bypassing agents exist, and those available were published before the approval of emi- 
| IMMUNE TOLER AN CE INDUC TION
| Defining the outcome of ITI
It is important to establish firm definitions not only of ITI success, but also when treatment has not succeeded. Widely adopted definitions of successful, partially successful, and unsuccessful ITI for patients with haemophilia A and inhibitors have been published previously (Table 1) . 17 The International workshop on ITI published many of these definitions, which are still relevant to clinical practice. 
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The UKHCDO has also considered these issues and, in their guidelines on the management of inhibitors, propose that a suitable criterion for defining tolerance and restoration of normal FVIII pharmacokinetics (PK) is a FVIII elimination half-life of >7 hours. 
| Conventional methods for ITI
The conventional methods for ITI include the "Bonn high-dose" regimen or variant protocols 33, 34 and the "Van Creveld Dutch lowdose" regimen, or variant protocols 35 (Table 2) . 17 In difficult-to-treat cases (see section 4.4), the Malmö protocol is an alternative option (Table 2) . 36 The pivotal International Immune Tolerance (I-IT) study, which randomised patients to low-dose (50 IU/kg FVIII, three times a week) or high-dose (200 IU/kg FVIII, daily) regimens, lacked statistical power to show therapeutic equivalence. 37 The FVIII dose did not affect success rate at the end of the study period, although patients receiving a high dose had a significantly shorter time to negative inhibitor titre. 37 Furthermore, a significantly greater number of bleeds was observed in the low-dose arm.
37
Initially, all ITI protocols utilised plasma-derived factor concentrate. However, with the advent of monoclonal antibody-purified and recombinant factor concentrates, there is now much discussion regarding product type (see next section). Furthermore, although the first ITI protocol was published in the 1970s, the optimal regimen has yet to be defined, partly because clinical studies do not necessarily involve similar patient cohorts and therefore cannot be compared directly.
In the event that ITI is successful and tolerance achieved, the authors recommend long-term continuous prophylaxis, to help maintain tolerance and to avoid rapid changes in dose.
| Predictors of outcome of conventional ITI
Reports on ITI outcomes collected in several international registries, albeit not always in agreement, have enabled the identification of numerous treatment-and patient-related factors that are predictive of ITI outcome. 17, 38 Treatment-related factors that may influence ITI outcome include inhibitor titre at ITI onset, the time elapsed between inhibitor diagnosis and initiating ITI, historical peak inhibitor titre, and peak inhibitor titre during ITI (Table 3 ). An inhibitor titre of <10 BU/mL at ITI onset is recognised as one of the main determinants of ITI outcome, positively affecting both the likelihood of success and the time taken to achieve success. 2, [13] [14] [15] [16] 38, 39 Although the usual recommendation is to delay ITI until the inhibitor titre is <10 BU/mL, but prefer- The Malmö protocol (option for use in difficult-to-treat patients) • High-dose FVIII plus immunomodulation (adsorption and suppression) • Cyclophosphamide 12-15 mg ⁄ kg IV daily for 2 days, then 2-3 mg ⁄ kg PO daily for 8-10 days • FVIII to achieve a 40%-100% FVIII level, followed by FVIII infusion every 8-12 h to achieve a 30%-80% FVIII level • IVIG 2.5-5 g IV immediately after the first FVIII infusion, followed by 0.4 g ⁄ kg daily on days 4-8 • Reported success rate, 59%-82% • Median time to success: 1 mo BID, twice daily; FVIII, factor VIII; ITI, immune tolerance induction; IV, intravenous; IVIG, intravenous immunoglobulin; pd-aPCC, plasma-derived activated prothrombin complex concentrate; PO, by mouth.
TA B L E 3 Potential predictors of outcome of conventional ITI
Potential predictor Evidence
Treatment-related factors
Inhibitor titre <10 BU/mL at ITI onset Supportive:
• An inhibitor titre of <10 BU/mL at ITI onset has been shown to positively affect both the likelihood of success and the time taken to achieve success in a number of studies 2, [13] [14] [15] [16] 38, 39, 41 Against:
• Successful ITI was achieved in 13 patients with an inhibitor titre ≥10 BU/mL when initiated within 1 mo of inhibitor detection 40 Time between inhibitor diagnosis and initiating ITI ≤5 yrs Supportive:
• Registry data, including those from the NAITR and the International IT Registry, found a significant association between achieving tolerance and the time elapsed between inhibitor diagnosis and ITI initiation, with improved outcomes for patients treated within 5 years of inhibitor detection 13, 16 Against:
• Data from the German registry show that the time interval between inhibitor detection and the start of ITI did not have a significant effect on ITI success 15 Historical peak inhibitor titre of <200 BU/mL Supportive:
• According to registry data (including those from the Italian PROFIT Registry, the NAITR, the International IT Registry, and the I-IT Study), a historical peak inhibitor titre of <200 BU/mL is associated with a successful ITI outcome 16, 37, 38 Low peak inhibitor titre during ITI Supportive:
• An inverse relationship between peak titre on ITI and a successful ITI outcome has been reported 37, 38 Factor dose Supportive of low dose:
• The NAITR found an inverse correlation between daily dose and success rate
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Supportive of high dose:
• The International IT Registry reported improved outcomes with high-dose FVIII product 16 No effect:
• The I-IT study found that dose did not affect success rates, although patients on a high FVIII dose had a significantly shorter time to negative inhibitor titre 37 
Product
Supportive of monoclonally purified and rFVIII products:
• High ITI success rates (up to 91%) are reported for patients treated with monoclonal and rFVIII concentrates 39, [42] [43] [44] Supportive of vWF-containing products:
• vWF has been speculated to modulate FVIII immunogenicity, 45 and some studies indicate that pd concentrates that contain vWF increase the likelihood of success when compared with pure FVIII concentrates 46, 47 No effect:
• Data from the International IT Registry and NAITR, as well as a meta-analysis of several studies, show that pd and rFVIII concentrate have similar outcomes when used for ITI 2, 13, 16, 48 Patient-related factors Young age at start of ITI Supportive:
• In the International IT Registry, young age at treatment start positively affected outcome (P < 0.001), 16 and the NAITR observed a trend towards a younger mean age in the successful group
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Against:
• The Spanish Registry reported that older patients achieved better results
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No effect:
• No correlation between age at ITI start and ITI outcome was observed in the German registry, the Grifols-ITI Study, or a European study of retrospective data from 22 centres in Italy, Germany and Spain 15, 46, 49 Ethnicity Supportive:
• A retrospective, single-centre analysis reported a significantly lower ITI success rate among African Americans (58% vs 92% in non-African Americans); however, the African American patients had higher pre-ITI inhibitor titres 50 No effect:
• No difference in success of ITI outcome between patients of different ethnicities was seen in the NAITR and I-IT Study, although it is worth noting that only 8% of patients in the I-IT study were African Americans 13, 37 FVIII genotype Supportive:
• Analysis of data from the Italian PROFIT Registry showed that patients carrying FVIII mutations associated with a high risk of inhibitor development had significantly worse outcomes than patients with lower-risk mutations 51 • A link between "high-risk" FVIII mutations and worse ITI outcome was also reported for two patients with an intron 22 inversion, who had a considerably longer duration to ITI success compared to patients with other mutation types 52 No effect:
• A study showed that the FVIII mutation type did not affect the chance of achieving successful ITI 
| ITI strategies for difficult-to-treat patients
An algorithm to assist the management of patients with inhibitors is shown in Figure 1 .
| The general patient unresponsive to firstline ITI
In the event of ITI not succeeding using a low-or high-dose regimen of 55 In another study, four children with severe haemophilia A and one adult with mild haemophilia A were treated with rituximab. 54 In three patients, the inhibitors disappeared, although FVIII PK did not completely normalise in two patients. 54 It is important to note that information on the longterm safety of rituximab is still lacking and this has raised concerns regarding its use, particularly in children. 
| Adults and older patients with inhibitors
There is resistance, by both patients and physicians, to initiate ITI in adults with haemophilia and inhibitors, mainly related to the perceived poor prognosis, demanding treatment regimens and high costs. 58 However, as discussed above, age at ITI initiation should be considered in a larger framework of putative prognostic factors, 58 because older age when starting ITI may not adversely affect the outcome in adult patients with recent-onset inhibitors. 49 In a retrospective observational study of nine patients with severe or moderately severe (≤2% FVIII activity) haemophilia and long-standing inhibitors (4-31 yrs) who underwent late ITI utilising recombinant FVIII products (regimens ranged from 50 IU/kg/3 times per week to 100 IU/kg/daily), seven achieved either partial or full success. 59 Similarly, in another study, 11 of 12 adult patients (<2% FVIII activity), with >24 months between inhibitor diagnosis and ITI, achieved either complete or partial success using a single vWF-containing plasma-derived FVIII (pdFVIII) product.
49
Although ITI is associated with high costs in adults, a study investigating the lifetime cost of ITI started in childhood vs prophylaxis and on-demand treatment with bypassing agents found that, while initial costs of ITI were high, long-term ITI was no more expensive than other therapies to which it was compared.
60
In the authors' view, the current data suggest that a course of conventional ITI may be justified in selected adults; however, the likelihood of success and long-term benefits need to be weighed against the cost (both financial and to the patient's QoL). In the light of this, the decision to initiate ITI should be taken by both the physician and the patient, with good support available for the patient.
This is particularly necessary in those with long-standing inhibitors. Triggers to initiate late ITI include poor QoL, frequent/severe bleeds poorly controlled and upcoming surgery. 58 In the event that ITI is unsuccessful, careful consideration must be made of the costs and the impact of second-line therapy. With little in the way of evidence-based guidelines, the management of older patients with F I G U R E 1 Algorithm for the management of patients with inhibitors, including initial inhibitor prevention approaches, assessment of ITI response, and therapeutic options in patients with a persistent inhibitor after ITI. For more information on inhibitor prevention and detection strategies, please see reviews by Kempton and White, and Coppola et al 11, 88 *Please note that rFVIIa is not licenced for prophylaxis in all countries. aPCC, activated prothrombin complex concentrate; FVIII, Factor VIII; ITI, immune tolerance induction; rFVIIa, recombinant activated factor VI haemophilia and inhibitors remains a challenge for haematologists; clinical experience plays a major role in decision making. 
| Patients with predictors of non-response
It is the authors' opinion that ITI should be considered for all patients with haemophilia A and inhibitors, even those with characteristics recognised as being predictive of a poor response. For example, favourable response rates were reported in a retrospective analysis of data for children and adults with haemophilia A (<2% FVIII activity) and inhibitors, many of whom had poor prognostic characteristics.
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Of the patients who underwent primary ITI (n = 41) or rescue ITI (n = 19), 36 of the 45 (80%) of patients who had one or more predictors of poor response to ITI achieved complete or partial success.
Furthermore, among the 23 patients with three or more predictors of poor response to ITI, 19 (83%) achieved success (complete: n = 10; partial: n = 9).
Good success rates with a high-dose ITI protocol in patients with characteristics predictive of a poor response to ITI have also been observed in data from the International Immune Tolerance Registry, the North American Immune Tolerance Registry (NAITR) and from two German studies. 61 Success in this patient subgroup appeared to be influenced by the dose and type of concentrate used, with an apparent advantage for high-dose ITI using vWF-containing pdFVIII concentrates over recombinant or vWF-free concentrates. 61 An interim report from the Observational ITI research programme has also shown a high ITI success rate using pdFVIII/vWF product in patients with at least one predictor for poor response to ITI. 62 However, in a meta-analysis involving 13 studies comprising 382 patients, no difference was found in the proportion of patients achieving successful ITI when treated with FVIII concentrates either containing or devoid of vWF. 
| Mild haemophilia A
The management of FVIII inhibitors in patients with mild haemophilia A is a challenge due to the older age at onset and seeming lower effectiveness of conventional ITI. [63] [64] [65] 
| Managing the psychosocial impact of unsuccessful ITI
In the light of the psychosocial burden imposed on patients and caregivers by inhibitors and their management, psychologists should be included in any comprehensive care team alongside physicians, nurses, social workers, and physical and occupational therapists. 8, 11 This ensures that treatment plans encompass both physical and psychosocial evaluations, as well as intervention strategies. 8, 11 To improve QoL, symptoms of mental health problems, low self-esteem, low coping skills, depression, anxiety, and substance abuse should be monitored. 8 Some psychosocial issues can be alleviated through selfcare, helping the patient correctly identify feelings, teaching anger management techniques, encouraging social contact with peers (for both the patient and the caregiver), as well as providing assistance to improve communication with family and the medical team. 8 Ongoing psychosocial care for both the patient and the caregiver is recommended to maintain an attitude of hope for the future, deal with feelings of guilt, and ensure that adequate educational assistance is available. 8, 9 For this reason, psychosocial assessments before and after treatment are as vital as physical assessments. It is also important to recognise that use of the term "failed ITI" may have strong negative connotations and it may be better to use the term "unsuccessful ITI".
| ALTERNATIVE NON -ITI TRE ATMENT APPROACHE S FOR PATIENTS WITH INHIB ITOR S
Treatments for patients with inhibitors continue to be investigated.
Prophylaxis with bypassing agents may be an appropriate treatment option for some patients who are unresponsive to ITI 30, 31 ; sequential or concomitant therapy with rFVIIa and pd-aPCC might be helpful in difficult-to-treat patients for whom monotherapy with either agent is ineffective. 74, 75 One study showed that a combination of low-dose While eradication of inhibitors will likely remain the first priority in inhibitor patients, the non-ITI therapies described here offer promising alternatives as they have the ability to improve haemostasis in the presence of inhibitors, despite differing modes of action.
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These molecules could provide more options for patients with inhibitors for on-demand or surgical treatment (OBI-1 and rVIIa-FP), as well as prophylaxis (emicizumab, concizumab, and fitusiran).
However, it is important to be aware of the potential limitations and side effects of these new agents, such as thrombotic complications.
| CON CLUS IONS
ITI is an effective but highly demanding approach to eradicate inhibitors in patients with haemophilia. While evidence-based guidelines and consensus recommendations are valuable, clinical experience continues to play a major role. This is especially the case when managing difficult-to-treat patients, such as those who are unresponsive to first-line ITI, older patients, and those with mild haemophilia A, haemophilia B, or predictors of poor response. Acute bleeds in patients unresponsive to ITI can be treated with on-demand haemostatic therapy, such as bypassing agents. Furthermore, prophylaxis with bypassing agents or, in haemophilia A, with emicizumab may be effective for patients not currently receiving ITI, including those in whom ITI has previously been unsuccessful. The inability to achieve successful ITI in 20%-40% of patients, the high costs of treatment, and the challenges of inhibitor management in both children and adults highlight the expectations from the new prophylactic agents and the need for innovative strategies for achieving immune tolerance.
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